Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Truist raised the firm’s price target on Verona Pharma (VRNA) to $57 from $44 and keeps a Buy rating on the shares. The firm cites the ...

BTIG raised the firm’s price target on Verona Pharma (VRNA) to $77 from $51 and keeps a Buy rating on the shares. The company’s Q4 ...

Verona Pharma (VRNA) stock in focus as company reports early sales for Q4 and 2024 thanks to its lung disease therapy ...

Ensifentrine (Ohtuvayre) acts as bronchodilator and non-steroidal anti-inflammatory agent. It is formulated as suspension for inhalational route of administration. Ohtuvayre is indicated for the ...

Chief executive David Zaccardelli said Ohtuvayre was off to an "exceptionally strong start," with more than 3,500 healthcare ...

(Ensifentrine + glycopyrrolate) is under clinical development by Verona Pharma and currently in Phase II for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase II drugs for ...

UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine, setting up regulatory filings in the first half of next year.